333 related articles for article (PubMed ID: 33666135)
21. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
Vanhove B; Duvaux O; Rousse J; Royer PJ; Evanno G; Ciron C; Lheriteau E; Vacher L; Gervois N; Oger R; Jacques Y; Conchon S; Salama A; Duchi R; Lagutina I; Perota A; Delahaut P; Ledure M; Paulus M; So RT; Mok CK; Bruzzone R; Bouillet M; Brouard S; Cozzi E; Galli C; Blanchard D; Bach JM; Soulillou JP
Eur J Immunol; 2021 Jun; 51(6):1412-1422. PubMed ID: 33576494
[TBL] [Abstract][Full Text] [Related]
22. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
[TBL] [Abstract][Full Text] [Related]
23. Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.
Makdasi E; Levy Y; Alcalay R; Noy-Porat T; Zahavy E; Mechaly A; Epstein E; Peretz E; Cohen H; Bar-On L; Chitlaru T; Cohen O; Glinert I; Achdout H; Israely T; Rosenfeld R; Mazor O
Viruses; 2021 Mar; 13(4):. PubMed ID: 33810465
[TBL] [Abstract][Full Text] [Related]
24. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
25. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
[TBL] [Abstract][Full Text] [Related]
26. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
Bertoglio F; Meier D; Langreder N; Steinke S; Rand U; Simonelli L; Heine PA; Ballmann R; Schneider KT; Roth KDR; Ruschig M; Riese P; Eschke K; Kim Y; Schäckermann D; Pedotti M; Kuhn P; Zock-Emmenthal S; Wöhrle J; Kilb N; Herz T; Becker M; Grasshoff M; Wenzel EV; Russo G; Kröger A; Brunotte L; Ludwig S; Fühner V; Krämer SD; Dübel S; Varani L; Roth G; Čičin-Šain L; Schubert M; Hust M
Nat Commun; 2021 Mar; 12(1):1577. PubMed ID: 33707427
[TBL] [Abstract][Full Text] [Related]
28. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern.
Cho H; Gonzales-Wartz KK; Huang D; Yuan M; Peterson M; Liang J; Beutler N; Torres JL; Cong Y; Postnikova E; Bangaru S; Talana CA; Shi W; Yang ES; Zhang Y; Leung K; Wang L; Peng L; Skinner J; Li S; Wu NC; Liu H; Dacon C; Moyer T; Cohen M; Zhao M; Lee FE; Weinberg RS; Douagi I; Gross R; Schmaljohn C; Pegu A; Mascola JR; Holbrook M; Nemazee D; Rogers TF; Ward AB; Wilson IA; Crompton PD; Tan J
Sci Transl Med; 2021 Oct; 13(616):eabj5413. PubMed ID: 34519517
[TBL] [Abstract][Full Text] [Related]
29. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.
Mor M; Werbner M; Alter J; Safra M; Chomsky E; Lee JC; Hada-Neeman S; Polonsky K; Nowell CJ; Clark AE; Roitburd-Berman A; Ben-Shalom N; Navon M; Rafael D; Sharim H; Kiner E; Griffis ER; Gershoni JM; Kobiler O; Leibel SL; Zimhony O; Carlin AF; Yaari G; Dessau M; Gal-Tanamy M; Hagin D; Croker BA; Freund NT
PLoS Pathog; 2021 Feb; 17(2):e1009165. PubMed ID: 33571304
[TBL] [Abstract][Full Text] [Related]
30. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.
Zhao S; Zhang H; Yang X; Zhang H; Chen Y; Zhan Y; Zhang X; Jiang R; Liu M; Liu L; Chen L; Tang W; Peng C; Gao X; Zhang Z; Shi Z; Gong R
Nat Commun; 2021 Aug; 12(1):4887. PubMed ID: 34373446
[TBL] [Abstract][Full Text] [Related]
31. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the molecular mechanism of SARS-CoV-2 antibodies.
Jin D; Wei J; Sun J
Biochem Biophys Res Commun; 2021 Aug; 566():45-52. PubMed ID: 34116356
[TBL] [Abstract][Full Text] [Related]
34. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
35. Stereotypic neutralizing V
Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J
Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677
[TBL] [Abstract][Full Text] [Related]
36. A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.
Beaudoin-Bussières G; Chen Y; Ullah I; Prévost J; Tolbert WD; Symmes K; Ding S; Benlarbi M; Gong SY; Tauzin A; Gasser R; Chatterjee D; Vézina D; Goyette G; Richard J; Zhou F; Stamatatos L; McGuire AT; Charest H; Roger M; Pozharski E; Kumar P; Mothes W; Uchil PD; Pazgier M; Finzi A
Cell Rep; 2022 Feb; 38(7):110368. PubMed ID: 35123652
[TBL] [Abstract][Full Text] [Related]
37. Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes.
Cheng L; Song S; Zhou B; Ge X; Yu J; Zhang M; Ju B; Zhang Z
Virol J; 2021 Apr; 18(1):87. PubMed ID: 33910569
[TBL] [Abstract][Full Text] [Related]
38. Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2.
Zhou X; Ma F; Xie J; Yuan M; Li Y; Shaabani N; Zhao F; Huang D; Wu NC; Lee CD; Liu H; Li J; Chen Z; Hong Y; Liu WH; Xiao N; Burton DR; Tu H; Li H; Chen X; Teijaro JR; Wilson IA; Xiao C; Huang Z
Cell Rep; 2021 May; 35(6):109109. PubMed ID: 33932326
[TBL] [Abstract][Full Text] [Related]
39. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
Bertoglio F; Fühner V; Ruschig M; Heine PA; Abassi L; Klünemann T; Rand U; Meier D; Langreder N; Steinke S; Ballmann R; Schneider KT; Roth KDR; Kuhn P; Riese P; Schäckermann D; Korn J; Koch A; Chaudhry MZ; Eschke K; Kim Y; Zock-Emmenthal S; Becker M; Scholz M; Moreira GMSG; Wenzel EV; Russo G; Garritsen HSP; Casu S; Gerstner A; Roth G; Adler J; Trimpert J; Hermann A; Schirrmann T; Dübel S; Frenzel A; Van den Heuvel J; Čičin-Šain L; Schubert M; Hust M
Cell Rep; 2021 Jul; 36(4):109433. PubMed ID: 34273271
[TBL] [Abstract][Full Text] [Related]
40. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
